Replies to post #143379 on Biotech Values

[dav1234]

Intuitive Surgical (ISRG +2.2%) should be bought , albeit selectively, says William Blair. The firm recommends using the recent weakness to pick it up. Its channel checks indicate the outlook for robotic surgery has never been stronger, however Zytiga drug approval is likely years away. The firm maintains an Outperform rating



silly question...why Zytinga reference in above blurb on ISRG?

[DewDiligence]

Tesaro (ticker: TSRO) IPO’s at $13.50/sh, raising $93M in gross proceeds (assuming exercise of underwriter’s option):

http://finance.yahoo.com/news/tesaro-inc-announces-pricing-initial-234808435.html

A feature story on TSRO was posted in #msg-76333277.

[DewDiligence]

TSRO plans phase-1/2 trial of ALK-inhibitor, TSR-011, in NSCLC and other cancers:

http://finance.yahoo.com/news/tesaro-announces-clearance-investigational-drug-203000058.html

Following identification of the maximum tolerated dose of TSR-011 in the dose escalation phase of the Phase 1/2 study, TESARO plans to evaluate TSR-011 in three parallel cohorts of patients: those with ALK+ non-small cell lung cancer (NSCLC) who have not been previously treated with ALK inhibitors, those with NSCLC who have progressed during treatment with other ALK inhibitors and those with other tumor types expressing ALK.

TSRO has risen about 15% since its Jun 2012 IPO @$13.50 (#msg-77039735).